Moderna and Merck Score Major Win Against Melanoma

Moderna and Merck have announced positive Phase 3 results for their INTerpath-001 melanoma treatment. This is a major milestone in the fight against melanoma, a type of skin cancer.

The study, known as INTerpath-001, aimed to evaluate the safety and efficacy of Moderna's mRNA-based therapy combined with Merck's anti-PD-1 checkpoint inhibitor.

Eric Lefkofsky, Founder and CEO of Tempus, congratulated the companies on their achievement, stating: 'Congratulations to Moderna and Merck on today’s positive Phase 3 results for INTerpath-001, a major milestone for melanoma treatment and the future of more personalized care.'

Lefkofsky's company is proud to partner with Moderna and Merck in support of this program, sequencing patients as it advances.